SCHEMBL5482843

SCHEMBL5482843

COC1CCCC(OC)C1

nearest known ligand 0.40

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.40
DPP7 Q9UHL4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14270060 1.00 DPP4 (0.40) DPP4DPP7
SCHEMBL245842 0.86
SCHEMBL5477828 0.86
SCHEMBL12203768 0.83
SCHEMBL22203127 0.83
SCHEMBL15325961 0.83
SCHEMBL16158122 0.83
SCHEMBL21285267 0.83
SCHEMBL12203388 0.83
SCHEMBL19451382 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3541803-B1 TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2020-12-23 EP disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
EP-1627901-B1 PRIMER, CONDUCTOR FOIL WITH RESIN, LAMINATE AND PROCESS FOR PRODUCING THE LAMINATE HITACHI CHEMICAL CO LTD (JP) 2020-02-19 EP disclosed
WO-2018097945-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC. (US) 2018-05-31 WO disclosed
WO-2018093579-A1 TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2018-05-24 WO disclosed
WO-2018093580-A1 TRIAZOLE PYRIDYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2018-05-24 WO disclosed
WO-2017192485-A1 HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2017-11-09 WO disclosed
US-9795927-B2 Manufacturing carbon molecular sieve membranes using a pyrolysis atmosphere comprising sulfur-containing compounds L'Air Liquide Société Anonyme Pour L'Étude Et L'Exploitation Des Procedes Georges (FR) 2017-10-24 US disclosed
US-20160184776-A1 MANUFACTURING CARBON MOLECULAR SIEVE MEMBRANES USING A PYROLYSIS ATMOSPHERE COMPRISING SULFUR-CONTAINING COMPOUNDS AMERICAN AIR LIQUIDE, INC. 2016-06-30 US disclosed
US-20160184775-A1 MANUFACTURING CARBON MOLECULAR SIEVE MEMBRANES USING A PYROLYSIS ATMOSPHERE COMPRISING SULFUR-CONTAINING COMPOUNDS L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) 2016-06-30 US disclosed
EP-1939692-A2 Method for preparation of lithographic printing plate FUJIFILM Corporation (JP) 2008-07-02 EP disclosed
US-20080051583-A1 NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-28 US disclosed
US-20070255064-A1 Imidazolium-Methyl Sulfites for Use as Starting Compounds for Producing Ionic Liquids BASF AKTIENGESELLSCHAFT (DE) 2007-11-01 US disclosed
US-20070185297-A1 Primer, conductor foil with resin, laminated sheet and method of manufacturing laminated sheet HITACHI CHEMICAL COMPANY, LTD. (JP) 2007-08-09 US disclosed
US-20070185297-A1 Primer, conductor foil with resin, laminated sheet and method of manufacturing laminated sheet HITACHI CHEMICAL COMPANY, LTD. (JP) 2007-08-09 US disclosed
US-7156907-B2 Multimeric dye structures HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) 2007-01-02 US disclosed
WO-2001030745-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-05-03 WO disclosed
EP-0634381-B1 Olefin oligomerization process AMOCO CORP (US) 1998-09-02 EP disclosed
US-5396013-A Boron trifluoride, proton promoter and polyether ALBEMARLE CORPORATION (US) 1995-03-07 US disclosed
EP-0634381-A1 Olefin oligomerization process ALBEMARLE CORPORATION (US) 1995-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070255064-A1 Imidazolium-Methyl Sulfites for Use as Starting Compounds for Producing Ionic Liquids CBR3, SCO2, PRMT5 DPP4 4707/4885DPP7 4776/4885
US-20080051583-A1 NOVEL INTERMEDIATE COMPOUNDS USEFUL IN THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES PPARG, PPARD, PPARA DPP4 1546/4885DPP7 1371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.